{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:03:58Z","timestamp":1793948638188,"version":"4.8.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.48030","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T16:01:53Z","timestamp":1645113713000},"page":"e2148030","source":"Crossref","is-referenced-by-count":76,"title":["Use of Lipid-, Blood Pressure\u2013, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease"],"prefix":"10.1001","volume":"5","author":[{"given":"Adam J.","family":"Nelson","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Kaltenbach","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn G.","family":"Morse","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein R.","family":"Al-Khalidi","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Cavender","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Gaynor","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julienne K.","family":"Kirk","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Magwire","sequence":"additional","affiliation":[{"name":"St Luke\u2019s Health System, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas"},{"name":"Parkland Health and Hospital System, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Pak","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Pop-Busui","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Richardson","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagri","family":"Senyucel","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle D.","family":"Kelsey","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha J.","family":"Pagidipati","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"issue":"3","key":"zoi211321r1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2337\/dc18-1773","article-title":"Long-term absolute risk for cardiovascular disease stratified by fasting glucose level.","volume":"42","author":"Bancks","year":"2019","journal-title":"Diabetes Care"},{"issue":"8","key":"zoi211321r2","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.2337\/dc08-0025","article-title":"Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study.","volume":"31","author":"Fox","year":"2008","journal-title":"Diabetes Care"},{"issue":"6","key":"zoi211321r3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","article-title":"Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age.","volume":"113","author":"Lloyd-Jones","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"zoi211321r4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.pcad.2019.07.001","article-title":"Atherosclerotic cardiovascular disease and heart failure: determinants of risk and outcomes in patients with diabetes.","volume":"62","author":"Nelson","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"zoi211321r5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.gheart.2015.04.003","article-title":"Reducing premature cardiovascular morbidity and mortality in people with atherosclerotic vascular disease: the World Heart Federation roadmap for secondary prevention of cardiovascular disease.","volume":"10","author":"Perel","year":"2015","journal-title":"Glob Heart"},{"issue":"7","key":"zoi211321r6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/CIRCULATIONAHA.119.041730","article-title":"Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease.","volume":"140","author":"Arnold","year":"2019","journal-title":"Circulation"},{"issue":"15","key":"zoi211321r7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1177\/2047487317729252","article-title":"Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR research to practice project.","volume":"24","author":"Arnold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"zoi211321r8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/FJC.0000000000000864","article-title":"Antihyperglycemic therapies with expansions of US Food and Drug Administration indications to reduce cardiovascular events: prescribing patterns within an academic medical center.","volume":"76","author":"Hamid","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"zoi211321r9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016835","article-title":"Gaps in evidence-based therapy use in insured patients in the United States with type 2 diabetes mellitus and atherosclerotic cardiovascular disease.","volume":"10","author":"Nelson","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"zoi211321r10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12933-018-0699-7","article-title":"Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease.","volume":"17","author":"Pantalone","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"zoi211321r11","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.2337\/dc20-0735","article-title":"Medicaid expansion and utilization of antihyperglycemic therapies.","volume":"43","author":"Sumarsono","year":"2020","journal-title":"Diabetes Care"},{"issue":"25","key":"zoi211321r12","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","article-title":"Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling.","volume":"72","author":"Vaduganathan","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi211321r13","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.76","article-title":"The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.","volume":"2","author":"Weng","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"issue":"4","key":"zoi211321r14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/amiajnl-2014-002747","article-title":"Launching PCORnet, a national patient-centered clinical research network.","volume":"21","author":"Fleurence","year":"2014","journal-title":"J Am Med Inform Assoc"},{"issue":"5","key":"zoi211321r15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/pds.v28.5","article-title":"Performance of a computable phenotype for identification of patients with diabetes within PCORnet: the Patient-Centered Clinical Research Network.","volume":"28","author":"Wiese","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi211321r16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/dom.2018.20.issue-S1","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials.","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"zoi211321r17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.tem.2019.07.004","article-title":"Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials.","volume":"30","author":"Caruso","year":"2019","journal-title":"Trends Endocrinol Metab"},{"key":"zoi211321r18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/cjs.10069","article-title":"Testing for equivalence of variances using Hartley\u2019s ratio.","volume":"38","author":"Frey","year":"2010","journal-title":"Can J Stat"},{"issue":"2","key":"zoi211321r19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/JAHA.117.007132","article-title":"National trends in nonstatin use and expenditures among the US adult population from 2002 to 2013: insights from Medical Expenditure Panel Survey.","volume":"7","author":"Salami","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"25","key":"zoi211321r20","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"12","key":"zoi211321r21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi211321r22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.","volume":"342","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi211321r23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi211321r24","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"9535","key":"zoi211321r25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"issue":"7","key":"zoi211321r26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/archinte.166.7.787","article-title":"Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.","volume":"166","author":"Danchin","year":"2006","journal-title":"Arch Intern Med"},{"issue":"14","key":"zoi211321r27","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.jacc.2016.01.050","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction.","volume":"67","author":"Evans","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"zoi211321r28","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/ndt\/gfn082","article-title":"A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.","volume":"23","author":"Palmer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"zoi211321r29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1161\/HYPERTENSIONAHA.120.16281","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use among hypertensive US adults with albuminuria.","volume":"77","author":"Chu","year":"2021","journal-title":"Hypertension"},{"issue":"8","key":"zoi211321r30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/JAHA.117.005999","article-title":"Quality of Care of the initial patient cohort of the Diabetes Collaborative Registry.","volume":"6","author":"Arnold","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"zoi211321r31","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"10225","key":"zoi211321r32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"395","author":"Collaboration","year":"2020","journal-title":"Lancet"},{"issue":"15","key":"zoi211321r33","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes.","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"10157","key":"zoi211321r34","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"23","key":"zoi211321r35","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"42","key":"zoi211321r36","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1093\/eurheartj\/ehy517","article-title":"Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction.","volume":"39","author":"Hall","year":"2018","journal-title":"Eur Heart J"},{"issue":"21","key":"zoi211321r37","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJM199805213382106","article-title":"The treatment of unrelated disorders in patients with chronic medical diseases.","volume":"338","author":"Redelmeier","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi211321r38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/JAHA.116.004264","article-title":"Race-sex differences in statin use and low-density lipoprotein cholesterol control among people with diabetes mellitus in the Reasons for Geographic and Racial Differences in Stroke Study.","volume":"6","author":"Gamboa","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"zoi211321r39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2018.02.019","article-title":"Trends and disparities in statin use and low-density lipoprotein cholesterol levels among US patients with diabetes, 1999-2014.","volume":"139","author":"Gu","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"zoi211321r40","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice.","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"zoi211321r41","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.amepre.2014.10.025","article-title":"Race-sex differences in the management of hyperlipidemia: the Reasons for Geographic and Racial Differences in Stroke study.","volume":"48","author":"Safford","year":"2015","journal-title":"Am J Prev Med"},{"issue":"13","key":"zoi211321r42","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.jcin.2020.05.043","article-title":"Racial differences in long-term cardiovascular outcomes: the need to move from description to action.","volume":"13","author":"Nanna","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"24","key":"zoi211321r43","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1056\/NEJMsa1405003","article-title":"Quality and equity of care in U.S. hospitals.","volume":"371","author":"Trivedi","year":"2014","journal-title":"N Engl J Med"},{"key":"zoi211321r44","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","article-title":"10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2019.","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"zoi211321r45","article-title":"The Cardiovascular Quality Improvement and Care Innovation Consortium: inception of a multicenter collaborative to improve cardiovascular care.","volume":"14","author":"Bradley","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"zoi211321r46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"24","key":"zoi211321r47","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","article-title":"2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.","volume":"72","author":"Das","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"zoi211321r48","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"zoi211321r49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.121.053766","article-title":"Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community.","volume":"144","author":"Nelson","year":"2021","journal-title":"Circulation"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2789133\/nelson_2022_oi_211321_1644504648.68491.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T07:45:58Z","timestamp":1674805558000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2789133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.48030","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}